Oncolytics Biotech Inc.: Business Overview, Financials & Competitive Analysis
Oncolytics Biotech Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Platform immunotherapy candidate with FDA Fast Track status and compelling Phase 2 efficacy data positioned in large unmet-need GI cancer markets. The company has achieved FDA Fast Track designation for colorectal and pancreatic cancer and is pursuing strategic partnerships to accelerate development and commercialization. Clinical data demonstrates substantial survival.
What is Oncolytics Biotech Inc.'s industry? Oncolytics Biotech Inc. (oncolyticsbiotech.com) operates in Oncology/Immuno-Oncology - Clinical-Stage Biotechnology. AskCyborg classifies Oncolytics Biotech Inc. under Oncology/Immuno-Oncology - Clinical-Stage Biotechnology in its company registry.
Oncolytics Biotech is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent designed to convert immunologically "cold" tumors "hot" by act...
Cyborg Score thesis
Platform immunotherapy candidate with FDA Fast Track status and compelling Phase 2 efficacy data positioned in large unmet-need...
Read the full analyst-debate transcript →Get the Latest Oncolytics Biotech Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeOncolytics Biotech Inc. Overview
Pro stress-test →Oncolytics Biotech is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent designed to convert immunologically "cold" tumors "hot" by activating innate and adaptive immune responses. The company is advancing pelareorep in combination with chemotherapy and checkpoint inhibitors in metastatic gastrointestinal cancers, where it has Fast Track designation from the FDA for colorectal and pancreatic cancer.
Strategic Profile
Pro stress-test →Oncolytics is developing pelareorep as a first-in-class double-stranded RNA immunotherapeutic with Fast Track Designation for colorectal and pancreatic cancer, as a platform immunotherapy for gastrointestinal tumors, supported by safety data from over 1,300 patients. Prior Phase 2 data (REO 022) showed median overall survival of 27 months and objective response rate of 33% versus approximately 11.2 months and 10% for standard therapy.
Competitive Landscape
Pro stress-test →The metastatic pancreatic cancer market represents $3 billion TAM with 15% CAGR through 2032, currently dominated by chemotherapy with no approved immunotherapy options available. Oncolytics competes in immuno-oncology against established checkpoint inhibitor developers and emerging oncolytic virus companies by targeting immunologically cold tumors in GI malignancies.
Industry Context
Oncolytics Biotech Inc. operates in Oncology/Immuno-Oncology - Clinical-Stage Biotechnology.
Key facts
Founded: 1998 · Headquarters: Calgary, Canada · Employees: N/A · Revenue: $0 · Market cap: N/A